register

News - Pharmaceuticals

Report urges policy reform as next gen vaccines rely on improved market access

Health Industry Hub | February 28, 2022 |

Pharma News: The COVID-19 pandemic has shone a spotlight on the need for timely access to vaccines. This is the case not only for safe and effective COVID-19 vaccines, which have been developed and funded at unparalleled speed, but also for other routine and novel vaccines.

The Valuing Vaccines: Ensuring Australia’s access to vaccines today and tomorrow report, commissioned by Sanofi Australia and independently developed by Dr Brendan Shaw (former CEO of Medicines Australia), has been released to inform current debates about health system reform including the HTA Review.

Jane Halton AO PSM, Chair of Coalition for Epidemic Preparedness Innovations said in the report “Now, 25 years on from its inception, with a review underway of Australia’s National Medicines Policy and following arguably the worst global pandemic in a century, it is time to consider the National Immunisation Program and Australia’s immunisation policies to ensure they continue to provide vaccines to the Australian community in a timely manner.”

The challenges in valuing and funding of vaccines were raised by several industry leaders during the 2021 House of Reps Inquiry into approval processes for new drugs and novel medical technologies.

Anne Harris, Country Manager of Pfizer, told the Committee during the Inquiry “…we do have some challenges currently with the process for vaccine evaluation. We know vaccines have a huge public health benefit, but it does take time for those benefits to come through. The current system devalues – the benefit upfront is valued more than the benefit later on. I would say that one example would be meningococcal B vaccines. We have struggled to get that through evaluation, not just with Pfizer, but across the industry. There’ve been several attempts, but it has not been able to be demonstrated, to get a positive recommendation. If there were an approach which truly valued preventative treatments differently to how they are valued against medicines, we would be able to have further access.”

According to the report, as we look to a post-pandemic world, the time is right to consider the way the Commonwealth makes decisions about investing in immunisation. The report finds the processes used to evaluate, value and fund vaccines are increasingly out of step with international best practice, are administratively cumbersome, and do not sufficiently take the full value of vaccination and disease prevention into account when making investment decisions. The report states “…the PBAC will not recommend a vaccine for listing on the NIP unless it is at the lower end of its acceptable ICER [incremental cost-effectiveness ratio] range…less than $15,000/QALY for a vaccine to be acceptable.”

The analysis highlights aspects of the current vaccine assessment system, which contribute to Australians waiting 1,375 days (or more than three years) on average for a vaccine to be funded once approved by the Therapeutic Goods Administration (TGA). By comparison, it takes an average 410 days for medicines to be reimbursed in Australia, which in itself is behind other developed world countries.

“The post-PBAC [Pharmaceutical Benefits Advisory Committee] process is particularly worth reviewing,” the report stated. “The fact that it can take an extra 90 to 100 days on average for vaccines to get through this process compared to medicines perhaps reflects the complicated and protracted process used in NIP tendering, procurement and budgeting that vaccines must undergo once the PBAC makes a positive recommendation. The requirement for approval by the Minister for Health for listing on the NIP and approval by federal cabinet for NIP recommendations costing $25 million or more in any one year, with no time limits on this process for the NIP, also has the potential to increase the time taken.

“An issue here is the Commonwealth’s focus more on securing the lowest price for vaccines at a moment in time and less on cementing Australia’s place in long term supply chains and relationships with the major vaccine companies worldwide.”

The Report urges stakeholders to leverage the learnings from the COVID-19 pandemic to ensure the policies and processes support timely evaluation and access to vaccines.

“The COVID-19 pandemic has demonstrated the value of vaccines to our society and the economy. Investing in vaccine research and development, manufacturing, supply and ultimately having early access to vaccines can protect us from preventable diseases,” Dr Shaw said.

The Report also highlights consistently low investment in the National Immunisation Program (NIP) as a concern, with the program receiving $454 million in 2020-21. He noted the world was on the cusp of a new era in vaccine innovation with the report identifying more than 10,000 clinical trials for vaccines underway worldwide, including new technologies designed to prevent illnesses such as cancer, Alzheimer’s disease, coronaviruses, RSV, multiple sclerosis, and allergies.

“A new era in vaccine innovation must be matched by new policies to ensure all Australians receive equitable and timely access to best-in-class vaccines, today and into the future. Australians shouldn’t need to wait over three years for most new vaccines to become available,” Dr Shaw commented.

Sanofi Australia and New Zealand General Manager for Vaccines, Regis Launay, said “We remain keen to work hand-in-hand with governments to offer constructive recommendations on how to maximise the impact of new vaccine technologies,” he said.

The report outlines a four-point plan to evaluate, reform and streamline Australia’s vaccine policies:

  1. Develop a long-term strategic plan for vaccines and the future of the NIP that complements the existing National Immunisation Strategy and preventative health initiatives.
  2. Reform Australia’s vaccine health technology assessment (HTA) methodology to ensure the full value of vaccine innovation is appropriately recognised and considered in funding decisions.
  3. Reform the post-HTA procurement process for NIP vaccines to remove duplicative processes and shift procurement from a ‘transactional’ to ‘strategic’ approach with industry.
  4. Create a framework to ensure that pandemic vaccination plan remains operationally ready in the face of rapidly evolving risk.
    Sanofi Australia supports a long-term strategic plan for vaccines and reform of the NIP as part of the HTA Review stemming from the new Strategic Agreement between the Australian Government and Medicines Australia, as well as the House of Representatives Inquiry into access to new medicines and medical technologies.

To access the report, click here.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.